Bolt Biotherapeutics (BOLT) Misses Q2 EPS by 124c
Tweet
Share
E-mailGet Alerts BOLT Hot Sheet
Join SI Premium – FREE
Bolt Biotherapeutics (NASDAQ: BOLT) reported Q2 EPS of ($4.57), $1.24 worse than the analyst estimate of ($3.33). Revenue for the quarter came in at $5 thousand versus the consensus estimate of $1.5 million.
For earnings history and earnings-related data on Bolt Biotherapeutics (BOLT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EquipmentShare.com (EQPT) Mentioned as Short at Blue Orca
- BlackBerry shares gain premarket as Q2 results, guidance beat estimates
- XCF Global delays stockholder meeting on three-way business combination
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
